SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Insilico Medicine Reports 40% Response Rate in Early Mesothelioma Trial

The company reported a 40% response rate at a 130 mg dose in an early mesothelioma trial.

Related stories